Shionogi launches CUVPOSA for pediatric chronic severe drooling
Links shared publicly online about this topic.
- 382total visits
Shionogi launches CUVPOSA for pediatric chronic severe drooling
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
View full resource at news-medical.net
Tags: Neurology, Cerebral Palsy, Children's Health, Shionogi, Cuvposa
Most Recently Shared on April 7, 2011 at 2:09 pm By:
Shionogi launches CUVPOSA for pediatric chronic severe drooling: Shionogi Inc., the U.S.-based group company of ... http://bit.ly/gMBd6q
Shionogi Inc. Announces FDA Approval Of CUVPOSA™ For The Treatment Of Chronic Severe Drooling In Pediatric Patients With Neurologic Conditions
medicalnewstoday.com — “Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patie” View full resource at medicalnewstoday.com
Most Recently Shared on July 30, 2010 at 11:39 am By:
Shionogi Inc. Announces FDA Approval Of CUVPOSA For The Treatment Of Chronic Severe Drooling In Pediatric Patients... http://mnt.to/f/3GLX
Advertisement
